Evidence Snapshot

High affinity nerve growth factor receptor

CHEMBL2815 SINGLE PROTEIN Homo sapiens

Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T19:51:40Z

Source · ChEMBL 36 via Core Engine Freshness · Sep 14, 2026, 4:51 AM KST As of · Sep 13, 2026

ChEMBL ChEMBL 36 CHEMBL2815

Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats High affinity nerve growth factor receptor as ChEMBL target CHEMBL2815, mapped to UniProt P04629. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor

High affinity nerve growth factor receptor

SINGLE PROTEIN · Homo sapiens

As of 2026-09-13

ChEMBL target ID

CHEMBL2815

Primary anchor for compounds, assays, approvals, and exports

ChEMBL 36 via Core Engine As of 2026-09-13

www.ebi.ac.uk

UniProt accession

P04629

High affinity nerve growth factor receptor

UniProt accession via ChEMBL component mapping As of 2026-09-13

www.uniprot.org

Disease evidence contract

Open Targets-ready proxy

ChEMBL drug mechanism + indication proxy

ChEMBL drug mechanism + indication proxy As of 2026-09-13

www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why High affinity nerve growth factor receptor matters

As of 2026-09-13

High affinity nerve growth factor receptor is reviewed as High affinity nerve growth factor receptor (UniProt P04629); High affinity nerve growth factor receptor shows approved-linked disease relevance led by cancer. 5 more disease programs remain visible in the same review block.; 2 linked drugs keep this evidence frame grounded.; the current evidence base includes 30 approved drugs, 8683 compounds, and 1136 assays, with lead potency reaching pChEMBL 10.8.

Protein context

High affinity nerve growth factor receptor

High affinity nerve growth factor receptor Sequence length is 796 aa.

Review this target as High affinity nerve growth factor receptor, mapped to UniProt P04629. Sequence length is 796 aa.

Protein source · UniProt accession via ChEMBL component mapping

UniProt P04629 Protein

Disease context

cancer

High affinity nerve growth factor receptor shows approved-linked disease relevance led by cancer. 5 more disease programs remain visible in the same review block. 2 linked drugs keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include REGORAFENIB, REPOTRECTINIB.

Start review with cancer because it currently carries approved-linked support. Linked drugs include REGORAFENIB, REPOTRECTINIB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record

Approved-linked 2 linked drugs

Activity base

Portfolio and assay base

ChEMBL currently tracks 30 approved drugs, 8683 compounds, and 1136 assays for this target. The dominant activity type is IC50. CHEMBL5914333 is the current potency anchor at pChEMBL 10.8.

Use CHEMBL5914333 as the tractability anchor when discussing potency (pChEMBL 10.8).

Activity source · ChEMBL 36 via Core Engine

30 approved pChEMBL 10.8

Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?

Review-ready Target Rationale

One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why High affinity nerve growth factor receptor matters before drilling into raw source blocks.

Jump to Review Rationale

Need stable protein naming or accession mapping?

UniProt Target Context

UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P04629, not just the summarized rationale.

Open Protein Context

Need disease fit or evidence level for program framing?

Disease Relevance & Evidence Level

ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why cancer is currently treated as approved-linked support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

8683

Total Compounds

1136

Total Assays

Approved Drugs

IC50: 10548.0, KI: 934.0, EC50: 69.0, KD: 442.0

Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Compound	pChEMBL	Type	Phase
No preferred name CHEMBL5914333	10.8	Kd	—
No preferred name CHEMBL6044141	10.5	Kd	—
No preferred name CHEMBL5770246	10.3	Kd	—
No preferred name CHEMBL5831552	10.2	Kd	—
No preferred name CHEMBL5963783	10.2	IC50	—

Approved Drugs

Structure	Compound	First Approval
	REPOTRECTINIB CHEMBL4298138	2023
	QUIZARTINIB CHEMBL576982	2023
	FEDRATINIB CHEMBL1287853	2019
	ENTRECTINIB CHEMBL1983268	2019
	LORLATINIB CHEMBL3286830	2018
	LAROTRECTINIB CHEMBL3889654	2018
	LAROTRECTINIB SULFATE CHEMBL3989939	2018
	MIDOSTAURIN CHEMBL608533	2017
	NINTEDANIB CHEMBL502835	2014
	PONATINIB CHEMBL1171837	2012
	CABOZANTINIB CHEMBL2105717	2012
	BOSUTINIB CHEMBL288441	2012
	CRIZOTINIB CHEMBL601719	2011
	SUNITINIB CHEMBL535	2006
	SORAFENIB CHEMBL1336	2005

← Target Page

Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T19:51:40Z

Source · ChEMBL 36 via Core Engine Freshness · Sep 14, 2026, 4:51 AM KST As of · Sep 13, 2026

ChEMBL ChEMBL 36 CHEMBL2815